Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Cost of Revenue (2020 - 2025)

Vivos Therapeutics has reported Cost of Revenue over the past 6 years, most recently at $5.9 million for Q4 2025.

  • Quarterly Cost of Revenue rose 267.46% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Dec 2025, up 63.38% year-over-year, with the annual reading at $6.9 million for FY2025, 14.79% up from the prior year.
  • Cost of Revenue was $5.9 million for Q4 2025 at Vivos Therapeutics, up from $403000.0 in the prior quarter.
  • Over five years, Cost of Revenue peaked at $5.9 million in Q4 2025 and troughed at $260000.0 in Q2 2025.
  • The 5-year median for Cost of Revenue is $1.4 million (2021), against an average of $1.5 million.
  • Year-over-year, Cost of Revenue plummeted 75.33% in 2024 and then skyrocketed 267.46% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $2.6 million in 2021, then tumbled by 64.76% to $901000.0 in 2022, then grew by 28.63% to $1.2 million in 2023, then skyrocketed by 38.14% to $1.6 million in 2024, then skyrocketed by 267.46% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Cost of Revenue are $5.9 million (Q4 2025), $403000.0 (Q3 2025), and $260000.0 (Q2 2025).